BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy
| Autor: | K. M. Curran, L. E. Hamil, Susan E. Lana, E. J. Ehrhart, Paul R. Avery, Julia D. Labadie, Jenna H Burton, Paula A. Schaffer, Chad Frank |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Vincristine Pathology medicine.medical_specialty General Veterinary Cyclophosphamide business.industry CHOP medicine.disease Malignancy Lymphoma 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure immune system diseases hemic and lymphatic diseases 030220 oncology & carcinogenesis medicine Immunohistochemistry business neoplasms Diffuse large B-cell lymphoma B cell medicine.drug |
| Zdroj: | Veterinary and Comparative Oncology. 15:1269-1279 |
| ISSN: | 1476-5810 |
| DOI: | 10.1111/vco.12263 |
| Popis: | Diffuse large B-cell lymphoma (DLBCL) is the most common haematopoietic malignancy in dogs. Recently, MYC and BCL2 expression levels determined with immunohistochemistry (IHC) were found to be prognostic in people with DLBCL. We hypothesized that canine DLBCL can be similarly subdivided into prognostic subtypes based on expression of MYC and BCL2. Cases of canine DLBCL treated with CHOP chemotherapy were retrospectively collected and 43 dogs had available histologic tissue and complete clinical follow-up. Median values of percent immunoreactive versus immunonegative cells were used to determine positive or negative expression status. Completion of CHOP was significantly associated with a positive outcome. Compared with human patients, our canine DLBCL patients had high IHC expression of both MYC and BCL2, and relative expression levels of one or both markers were not associated with clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text